摘要
特应性皮炎(AD)是一种慢性、复发性、炎症性、瘙痒性皮肤病。其发病机制复杂,目前认为与遗传、环境、皮肤屏障异常及免疫系统紊乱有关。皮肤屏障功能障碍与丝聚蛋白(FLG)、兜甲蛋白(LOR)、内披蛋白(IVL)等的下调有关。Th2型皮肤炎症是AD的基本特征,IL4和IL-13是AD发病的重要细胞因子。本维莫德乳膏作为芳香烃受体/核因子E2相关因子(AHR/NRF2)的双重激活剂对AD的多种致病机制具有调节作用,本文就目前本维莫德乳膏治疗AD的研究进展进行综述。
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory, pruritus skin disease. Its pathogenesis is complex, and it is currently believed to be related to heredity, environment, abnormal skin barrier and immune system disorder. Skin barrier dysfunction is associated with down regulation of Filaggrin (FLG), Loricrin (LOR), and Involucrin (IVL). Th2 skin inflammation is a basic feature of AD, and IL4 and IL-13 are important cytokines in AD pathogenesis. As a double activator of aryl hydrocarbon receptor/nuclear factor E2-related factor 2 (AHR/NRF2), Benvitimod cream has a regulatory effect on various pathogenic mechanisms of AD. This paper reviews the current research progress of Benvitimod in the treatment of atopic dermatitis.
出处
《临床医学进展》
2023年第4期5634-5640,共7页
Advances in Clinical Medicine
